In the last decades tumor angiogenesis has become a very active area of research, resulting in the introduction of anti-angiogenic drugs in cancer therapy, such as the anti-VEGF antibody bevacizumab [26] and the tyrosine kinase inhibitors like sunitinib or sorafenib [27]. The gene discussed is VEGFA; the disease is cancer.